Department of Nuclear Medicine, Royal North Shore Hospital, and Faculty of Health Sciences, University of Sydney, Sydney, Australia.
Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard-Karls-Universität, Tübingen, Germany.
Mol Imaging Biol. 2018 Feb;20(1):4-20. doi: 10.1007/s11307-017-1123-5.
The 6th annual meeting to address key issues in positron emission tomography (PET)/magnetic resonance imaging (MRI) was held again in Tübingen, Germany, from March 27 to 29, 2017. Over three days of invited plenary lectures, round table discussions and dialogue board deliberations, participants critically assessed the current state of PET/MRI, both clinically and as a research tool, and attempted to chart future directions. The meeting addressed the use of PET/MRI and workflows in oncology, neurosciences, infection, inflammation and chronic pain syndromes, as well as deeper discussions about how best to characterise the tumour microenvironment, optimise the complementary information available from PET and MRI, and how advanced data mining and bioinformatics, as well as information from liquid biomarkers (circulating tumour cells and nucleic acids) and pathology, can be integrated to give a more complete characterisation of disease phenotype. Some issues that have dominated previous meetings, such as the accuracy of MR-based attenuation correction (AC) of the PET scan, were finally put to rest as having been adequately addressed for the majority of clinical situations. Likewise, the ability to standardise PET systems for use in multicentre trials was confirmed, thus removing a perceived barrier to larger clinical imaging trials. The meeting openly questioned whether PET/MRI should, in all cases, be used as a whole-body imaging modality or whether in many circumstances it would best be employed to give an in-depth study of previously identified disease in a single organ or region. The meeting concluded that there is still much work to be done in the integration of data from different fields and in developing a common language for all stakeholders involved. In addition, the participants advocated joint training and education for individuals who engage in routine PET/MRI. It was agreed that PET/MRI can enhance our understanding of normal and disrupted biology, and we are in a position to describe the in vivo nature of disease processes, metabolism, evolution of cancer and the monitoring of response to pharmacological interventions and therapies. As such, PET/MRI is a key to advancing medicine and patient care.
第六届正电子发射断层扫描（PET）/磁共振成像（MRI）重点问题年度会议于 2017 年 3 月 27 日至 29 日再次在德国图宾根举行。在为期三天的特邀全体会议演讲、圆桌讨论和对话委员会审议中，与会者对 PET/MRI 的当前临床和研究工具状态进行了批判性评估，并试图规划未来方向。会议讨论了 PET/MRI 的使用和在肿瘤学、神经科学、感染、炎症和慢性疼痛综合征中的工作流程，以及更深入地讨论如何最好地描述肿瘤微环境，优化来自 PET 和 MRI 的互补信息，以及如何利用先进的数据挖掘和生物信息学，以及液体生物标志物（循环肿瘤细胞和核酸）和病理学信息，来更全面地描述疾病表型。一些在前几次会议上占据主导地位的问题，例如基于磁共振的 PET 扫描衰减校正（AC）的准确性问题，最终被认为在大多数临床情况下已经得到充分解决。同样，用于多中心试验的 PET 系统标准化能力得到了确认，从而消除了对更大规模临床成像试验的一个感知障碍。会议公开质疑 PET/MRI 是否应在所有情况下都用作全身成像方式，或者在许多情况下，它是否最好用于对单个器官或区域中先前确定的疾病进行深入研究。会议得出的结论是，在整合来自不同领域的数据和为所有相关利益方开发通用语言方面仍有许多工作要做。此外，与会者提倡对从事常规 PET/MRI 的个人进行联合培训和教育。会议达成共识，认为 PET/MRI 可以增强我们对正常和紊乱生物学的理解，并且我们能够描述疾病过程、代谢、癌症演变以及对药理干预和治疗反应的监测的体内本质。因此，PET/MRI 是推进医学和患者护理的关键。
